Terms: = Ovarian cancer AND STIL, SIL, 6491, ENSG00000123473, Q15468 AND Prognosis
6 results:
1. Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Kang OJ; Lee SW; Kim JH; Park JY; Suh DS; Kim DY; Kim JH; Kim YM; Kim YT
Int J Gynecol Cancer; 2023 Nov; 33(11):1743-1749. PubMed ID: 37541685
[TBL] [Abstract] [Full Text] [Related]
2. Fallopian Tube Lesions in Women at High Risk for ovarian cancer: A Multicenter Study.
Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
[TBL] [Abstract] [Full Text] [Related]
3. Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer.
Wang J; Sharma A; Ghamande SA; Bush S; Ferris D; Zhi W; He M; Wang M; Wang X; Miller E; Hopkins D; Macfee M; Guan R; Tang J; She JX
PLoS One; 2013; 8(11):e78393. PubMed ID: 24244307
[TBL] [Abstract] [Full Text] [Related]
4. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
Lo CW; Chen MW; Hsiao M; Wang S; Chen CA; Hsiao SM; Chang JS; Lai TC; Rose-John S; Kuo ML; Wei LH
Cancer Res; 2011 Jan; 71(2):424-34. PubMed ID: 21123455
[TBL] [Abstract] [Full Text] [Related]
5. Clinical implication of serum sil-2R levels in ovarian cancer.
Wang S; Cai G; Lu Y
J Tongji Med Univ; 1998; 18(2):126-8. PubMed ID: 10806842
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract] [Full Text] [Related]
